The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.
 
Keith Dredge
Employment - Zucero Therapeutics
Stock and Other Ownership Interests - Progen
Patents, Royalties, Other Intellectual Property - Zucero Therapeutics (Inst)
 
Todd Brennan
No Relationships to Disclose
 
Michael Paul Brown
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pharmaust (Inst); Roche (Inst); Zucero Therapeutics (Inst)
 
Jason D. Lickliter
No Relationships to Disclose
 
Darryn Bampton
Employment - Zucero Therapeutics
 
Edward Hammond
Employment - Zucero Therapeutics
 
Liwen Lin
No Relationships to Disclose
 
Yiping Yang
No Relationships to Disclose
 
Michael Millward
No Relationships to Disclose